Indo Us Biotech Balance Sheet
- Market cap
- ₹146 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹52.34 – ₹98.15
As of FY25, Indo Us Biotech had total assets of ₹94.76 crore and borrowings of ₹17.49 crore, against shareholders' equity of ₹186 crore — a debt-to-equity ratio of 0.35.
Indo Us Biotech balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | FY25 |
|---|---|
| Equity capital | 120 |
| Reserves | 65.6 |
| Borrowings | 17.49 |
| Other liabilities | 11.66 |
| Total liabilities | 94.76 |
| Fixed assets | 51.02 |
| Capital work in progress | 45 |
| Investments | 21.87 |
| Other assets | 21.87 |
| Total assets | 94.76 |
Balance sheet ratios
- Debt to equity
- 0.35
- Book value per share
- ₹25.51
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Indo Us Biotech balance sheet — frequently asked questions
What is the total debt of Indo Us Biotech?
Indo Us Biotech reported borrowings of ₹17.49 crore as of FY25.
What is Indo Us Biotech's debt-to-equity ratio?
Based on the FY25 balance sheet, Indo Us Biotech's debt-to-equity ratio is 0.35 — borrowings of ₹17.49 crore against equity capital and reserves of ₹186 crore.
What are Indo Us Biotech's total assets?
Indo Us Biotech's total assets were ₹94.76 crore as of FY25, including fixed assets of ₹51.02 crore and investments of ₹21.87 crore.
What is the book value per share of Indo Us Biotech?
The book value per share of Indo Us Biotech is ₹25.51, based on the latest reported balance sheet.
Same Data For Peers
Trade Indo Us Biotech With ATS
Track INDOUS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.